Written and maintained by CASRAI Editorial Board
Last updated
Any clinical trial conducted in Ethiopia needs authorization from the Ethiopian Food and Drug Authority (EFDA) — the country’s national medicines regulator — in addition to ethical clearance from an accredited ethics review body. For sponsors and CROs used to a single-regulator model, the distinguishing feature of Ethiopia’s system is that ethical review runs on two tiers: routine protocols go to an institutional Research Ethics Committee (REC) or Ethics Review Committee (ERC), while sensitive protocols — including most clinical trials, international collaborations, and studies involving the export of biological specimens — also require review by the National Research Ethics Review Committee (NRERC). This guide covers EFDA’s authorization pathway, what a complete application requires, and how the two ethics-review tiers fit together.
Legal Basis and Regulatory Framework
EFDA’s authority over clinical trials derives from the Ethiopian Food, Medicine and Healthcare Administration and Control Proclamation (Proclamation No. 661/2009) and the clinical trial authorization guidelines EFDA has issued under it. EFDA has periodically revised its Clinical Trial Authorization (CTA) Guideline as international regulatory expectations and Ethiopia’s own institutional capacity have evolved — sponsors should confirm they are working from EFDA’s current published edition rather than an older cached copy, since national regulators in this position (see also Ghana FDA and Nigeria’s NAFDAC) tend to update trial-authorization guidance more frequently than they update the underlying enabling proclamation.
EFDA sits within a broader set of national medicines regulators that WHO’s Global Benchmarking Tool (GBT) has assessed for regulatory system maturity; Ethiopia’s regulatory system has been part of that ongoing benchmarking process, alongside peer African regulators building out comparable clinical-trial-oversight capacity.
Who Authorizes Clinical Trials in Ethiopia
EFDA is the statutory authority responsible for reviewing and authorizing the conduct of clinical trials of medicines, vaccines, and related investigational products in Ethiopia. Authorization from EFDA is required in addition to, not instead of, ethical review. Ethiopia’s ethics-review structure has two tiers:
- Institutional Research Ethics Committees / Ethics Review Committees (RECs/ERCs) — based at universities, research institutes, and hospitals, these review the majority of research protocols involving human participants, including routine clinical studies.
- The National Research Ethics Review Committee (NRERC) — a higher-tier committee that reviews protocols institutional RECs are not mandated to clear alone: studies involving international collaboration, the transfer of biological specimens abroad, and, in practice, most clinical trials submitted to EFDA. Sponsors planning a multi-site or internationally sponsored trial in Ethiopia should expect NRERC review to sit alongside their institutional REC/ERC approval and their EFDA authorization, not to substitute for either.
A trial needs both EFDA’s regulatory authorization and the applicable tier of ethics-committee approval before enrollment can begin; neither approval substitutes for the other.
The Clinical Trial Application Process
Sponsors submit a Clinical Trial Application (CTA) to EFDA, organized around what EFDA’s guidance frames as four pillars: clinical trial regulation (the application, protocol, and informed-consent requirements themselves), Good Clinical Practice (GCP) compliance, the ethics-review record, and pharmacovigilance. In practice, a complete CTA dossier typically includes:
- A completed clinical trial application form
- The study protocol, covering rationale, objectives, methodology, and statistical analysis plan
- The Investigator’s Brochure
- Informed consent form(s) and participant information materials
- A letter documenting Ethics Committee/REC (and, where applicable, NRERC) approval, or evidence that ethics review is in progress where final approval is still pending
- Evidence of participant insurance/indemnity coverage
- Investigational product quality and manufacturing information
EFDA’s guidance calls for electronic submission through its designated regulatory information system, alongside the physical documentation its process requires. EFDA does not publish a single, universally-cited fee schedule or review-timeline figure in the way some peer regulators do; sponsors should confirm current fees and expected review timelines directly with EFDA (via its Electronic Regulatory Information System, ERIS) before planning a submission around an assumed date.
GCP Compliance and Ongoing Oversight
Trials authorized by EFDA must be conducted to Good Clinical Practice (GCP) standards. Once a trial is underway, sponsors are expected to report serious adverse events within EFDA’s specified timelines, document protocol deviations, maintain ongoing engagement with the relevant ethics committee(s), and submit a final Clinical Study Report on completion. EFDA’s clinical trial function is one of several it operates alongside medicine registration, Good Manufacturing Practice (GMP) inspection, pharmacovigilance, and medical device regulation — the same institutional base most peer African national regulators build their clinical-trial-oversight function on.
Ethiopia in Context: Comparing EFDA to Peer African Regulators
Ethiopia is one of a growing list of African countries with a formal national clinical-trial-authorization pathway, alongside Ghana’s FDA, Nigeria’s NAFDAC, South Africa’s SAHPRA, Egypt’s EDA, and Kenya’s Pharmacy and Poisons Board. What distinguishes Ethiopia’s system in practice is its two-tier ethics structure — the NRERC layer above institutional RECs/ERCs for sensitive and internationally-collaborative protocols — which sponsors accustomed to a single-ethics-committee model should plan for explicitly. For trials spanning multiple African jurisdictions, see this site’s overview of the African Medicines Agency and what its emerging multi-country review pathway means for sponsors weighing where a shared submission might reduce duplicated review.
Frequently Asked Questions
Does EFDA authorization replace the need for ethics committee approval in Ethiopia?
No. EFDA’s authorization and ethics-committee approval are separate, both-required steps. Most clinical trials also require review by the National Research Ethics Review Committee (NRERC) in addition to an institutional REC/ERC, given the international-collaboration and specimen-transfer criteria that typically apply to sponsored clinical trials.
What is the National Research Ethics Review Committee (NRERC)?
The NRERC is Ethiopia’s higher-tier national ethics review body, distinct from the institutional Research Ethics Committees (RECs) or Ethics Review Committees (ERCs) based at universities, hospitals, and research institutes. It reviews research categories institutional committees are not mandated to clear alone — including, in practice, most clinical trials, studies with international collaboration, and research involving export of biological specimens.
Where can sponsors find EFDA’s current clinical trial authorization guideline?
EFDA publishes its clinical trial guidance through its own site (efda.gov.et) and its Electronic Regulatory Information System (ERIS, eris.efda.gov.et). Because EFDA has issued more than one edition of its Clinical Trial Authorization Guideline, sponsors should confirm they are working from the current edition directly with EFDA rather than relying on an older cached PDF.
Does EFDA require GCP compliance?
Yes. EFDA requires trials it authorizes to be conducted to Good Clinical Practice (GCP) standards, alongside the national regulatory requirements set out in its Clinical Trial Authorization Guideline.
Sources
Ethiopian Food and Drug Authority (EFDA) publication and guideline pages (efda.gov.et, eris.efda.gov.et) — EFDA’s site returned an access error to automated verification at the time of writing, so the specifics above are corroborated against multiple independent secondary sources rather than EFDA’s own current-edition PDF: PharmaRegulatory.in’s country-specific overview of EFDA’s regulatory mandate and its dedicated page on clinical trial oversight and ethics approval in Ethiopia; the EDCTP-supported ERA-LEARN project record on strengthening NRERC and EFDA capacity for clinical trials in Ethiopia; and peer-reviewed literature on Ethiopia’s IRB/ethics-review landscape, including a 2023 study on Institutional Review Board composition and capacity in Addis Ababa. Sponsors should verify current fees, review timelines, and the applicable guideline edition directly with EFDA before submitting an application.
